These concepts have inspired ongoing clinical trials, which are testing the efficacy of treating myelofibrosis patients with drugs that either increase GATA1 content, restore megakaryocyte maturation [16], or inhibit TGF-β signaling [17]. This evidence concerns the gene TGFB1 and myelofibrosis.